BRAF and adenocarcinoma: From December 2014 to July 2019, 11 patients with BRAF-V600E-mutation NSCLC were included in the MATCH-R study, all diagnosed with adenocarcinoma and negative for EGFR, ALK, ROS1, KRAS, and HER2.